Latest news on diagnostics and therapy
Frankfurt am Main. Current topics in neurology were once again the focus of the Neuroforum 2025, organized by Novartis. The multiple sclerosis session focused on how disease activity in MS can be better assessed and how patients can be stratified to enable the most optimal personalized therapy. Serum neurofilament light chains (sNfL) are an activity marker that has entered clinical practice. In addition to imaging techniques such as magnetic resonance imaging (MRI) and clinical findings, this marker can contribute to personalized treatment decisions in active relapsing-remitting multiple sclerosis [1–3]. Modern therapies such as the anti-CD20 antibody ofatumumab have been able to sustainably reduce sNfL levels [4]. Current data on ofatumumab over an observation period of up to seven years are available, among other things, from the open-label extension study ALITHIOS [5, 6].
Arzte zeitung
